Skin Cancer Center Charité, Department of Dermatology, Charité University Medicine, Berlin, Germany. martina.ulrich @ charite.de
Dermatology. 2010;220(1):15-24. doi: 10.1159/000254893. Epub 2009 Nov 11.
Actinic keratoses (AK) represent cutaneous carcinoma in situ and have previously been evaluated by reflectance confocal microscopy (RCM). Treatment of AK with imiquimod (IMIQ) 5% cream has been shown to 'highlight' subclinical lesions.
The aim of this study was to test the applicability of RCM for noninvasive monitoring of actinic field cancerization and detection of subclinical AK.
AK and surrounding skin sites with no apparent AK of 11 volunteers were selected for imaging and subsequently classified as 'clinical' and 'subclinical' AK. IMIQ was used 3 times weekly for 4 weeks.
RCM was able to detect morphologic features of AK in both clinical and subclinical AK; features were more pronounced in clinical lesions. The immunomodulatory response induced by IMIQ was visualized by RCM.
Our findings indicate that RCM allows noninvasive monitoring of treatment response in vivo and permits early detection of subclinical AK, thus substantiating the incentive for therapy.
光化性角化病(AK)代表原位皮肤癌,以前曾通过反射共聚焦显微镜(RCM)进行评估。咪喹莫特(IMIQ)5%乳膏治疗 AK 已被证明可以“突出”临床前病变。
本研究旨在测试 RCM 用于非侵入性监测光化性皮肤病和检测临床前 AK 的适用性。
选择 11 名志愿者的 AK 和周围无明显 AK 的皮肤部位进行成像,随后分为“临床”和“临床前”AK。IMIQ 每周使用 3 次,持续 4 周。
RCM 能够检测到临床和临床前 AK 中的 AK 的形态特征;临床病变中的特征更为明显。RCM 可以观察到 IMIQ 诱导的免疫调节反应。
我们的研究结果表明,RCM 允许对体内治疗反应进行非侵入性监测,并允许早期检测临床前 AK,从而为治疗提供依据。